您所在的位置: 首页 --> 导师团队 --> 朱军

导师基本信息

  • 姓名:朱军
  • 性别:
  • 民族:汉族
  • 科室:淋巴肿瘤内科
  • 职称:主任医师
  • 专业:肿瘤学 ,肿瘤内科学
  • E-MAIL: zhujun@csco.org.cn

学术论文 | 研究方向 | 科研项目

Jiao Li, Ning Ding, Xiaogan Wang, Lan Mi, Lingyan Ping, Xuan Jin, Yalu Liu, Zhitao Ying, Yan Xie, Weiping Liu, Yuqin Song and Jun Zhu. EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R‑CHOP ,Cancer Cell International ,14;17:70.

Ping L#, Ding N#, Shi Y, Feng L, Li J, Liu Y, Lin Y, Shi C, Wang X, Pan Z, Song Y, Zhu J*. The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. ,Oncotarget ,

Zheng W, Ren H, Ke X, Xue M, Zhang Y, Xie Y, Lin N, Tu M, Liu W, Ping L, Ying Z, Zhang C, Deng L, Wang X, Song Y, Zhu J. PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma. ,Chin J Cancer Res ,29(1):66-74.

Jiao Li, Xiaogan Wang, Yan Xie, Zhitao Ying, Weiping Liu, Lingyan Ping, Chen Zhang, Zhengying Pan, Ning Ding, Yuqin Song, Jun Zhu. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton’s tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.,International Journal of Cancer,142(1):202-213

Cerebrospinal Fluid Proteins Identification Facilitatesthe Differential Diagnosis of Central Nervous System Diffuse Large B Cell Lymphoma ,Journal of Cancer ,2017; 8(17): 3631-3640

Liu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, Song YQ, Zhu J. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. ,Leuk Lymphoma. ,2016;57(6):1355-62.

Jia J, Song Y, Lin N, Liu W, Ping L, Zheng W, Wang X, Xie Y, Tu M, Zhang C, Ying Z, Deng L, Ding N, Zhu J. Clinical features and survival of extranodal natural killer/T cell lymphoma with and without hemophagocytic syndrome. ,Ann Hematol. ,2016;95(12):2023-2031

Zhang X, Zhu J*, Song Y, Ping L, Zheng W. Clinical characterization and outcome of primary bone lymphoma: a retrospective study of 61 Chinese patients. ,Sci Rep ,6:28834.

Lijuan Deng, Yuqin Song, Ken H. Young, Shimin Hu, Ning Ding, Weiwei Song, Xianghong Li, Yunfei Shi, Huiying Huang, Weiping Liu, Wen Zheng, Xiaopei Wang, Yan Xie, Ningjing Lin, Meifeng Tu, Lingyan Ping, Zhitao Ying, Chen Zhang, Yingli Sun, Jun Zhu Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin ,Oncotarget ,2015;6(28):25061-25075

Ying Z, Huang XF, Xiang X, Liu Y, Kang X, Song Y, Guo X, Liu H, Ding N, Zhang T, Duan P, Lin Y, Zheng W, Wang X, Lin N, Tu M, Xie Y, Zhang C, Liu W, Deng L, Gao S, Ping L, Wang X, Zhou N, Zhang J, Wang Y, Lin S, Mamuti M, Yu X, Fang L, Wang S, Song H, Wang G, Jones L, Zhu J, Chen SY. A safe and potent anti-CD19 CAR T cell therapy.,Nat Med.,

Sun Y#, Ding N#, Song Y#, Yang Z, Liu W*, Zhu J*, Rao Y*.Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.,Leukemia,

Liu WP, Wang XP, Zheng W, Xie Y, Tu MF, Lin NJ, Ping LY, Ying ZT, Zhang C, Deng LJ, Ding N, Wang XG, Song YQ*, Zhu J*. Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma. ,Ann Hematol. ,97:133-9.

Shi C, Li X, Wang X, Ding N, Ping L, Shi Y, Mi L, Lai Y, Song Y, Zhu J. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.,J Hematol Oncol.,11:43.

Zhu J, Huang H, Chen H, Zhang X, Li Z, Wu D, Zhou D, Song Y, Hu Y, Liang Y, Ren H, Huang H, Li N, Chen H, Hu J, Li J, Meng R, Wu J, Yu D, Huang X. Plerixafor and granulocyte-colony-stimulating factor for mobilization of hematopoietic stem cells for autologous transplantation in Chinese patients with non-Hodgkin's lymphoma: a randomized Phase 3 study. ,Transfusion. ,58(1):81-87

Liu Y, Wang X, Ding N, Mi L, Ping L, Jin X, Li J, Xie Y, Ying Z, Liu W, Zhang C, Deng L, Song Y, Zhu J. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP. ,BMC Cancer. ,17:743.

新型Btk小分子抑制剂抗B细胞淋巴瘤作用机制研究 , 课题负责人 , 2015.1.1~2018.12.31, 国家自然科学基金/81470368

Btk抑制剂抗B细胞淋巴瘤作用机制研究 , 课题负责人 , 2015.1.1~2017.12.31, 北京市自然科学基金/7152030

复发难治淋巴系统恶性肿瘤基于造血干细胞移植的治疗模式研究 , 课题负责人 , 2015.1.1~2017.12.31, 北京市医院管理局扬帆计划/XMLX201503

MT-R方案联合自体造血干细胞移植治疗初治原发中枢神经系统淋巴瘤的疗效及安全性评价 , 课题负责人 , 2014.6.1~2017.5.31, 北京卫计委首都卫生发展科研专项/首发2014-2-2153

MT-R方案联合自体造血干细胞移植治疗初治原发中枢神经系统淋巴瘤的疗效及安全性评价 , 课题负责人 , 2014.6.1~2017.5.31, 北京卫计委首都卫生发展科研专项/首发2014-2-2153

社会任职

  • 中国抗癌协会血液肿瘤专业委员会常委
  • 中国抗癌协会淋巴瘤专业委员会副主任委员
  • CSCO执委会委员
  • 《中国医院用药与评价》杂志编委会副主任
  • 《淋巴瘤.白血病》杂志编委
  • 国家自然科学基金和863项目评审专家

学习、工作经历

  • 2004.8.1~2005.2.1,清华大学公共管理学院公共卫生管理高级研修班
  • 2001.2.1~2001.3.1,复旦大学医学院国家药品临床研究培训班学习
  • 1999.6.1~2011.11.9,北京大学临床肿瘤学院淋巴血液肿瘤科,副主任医师,科主任
  • 1998.6.1~1999.6.1,北京大学临床肿瘤学院淋巴血液肿瘤科主治医师